Altaris Capital Partners has agreed to acquire Simulations Plus, a health technology company, in a take-private transaction valued at $375 million. The deal was announced this week and will transition Simulations Plus from a publicly traded firm to a private entity under Altaris’ ownership, according to pehub.com.
The acquisition process involves Altaris purchasing all outstanding shares of Simulations Plus at a premium to the company’s recent trading price. The transaction is expected to close in the coming months, subject to customary closing conditions and regulatory approvals. The deal reflects Altaris’ continued interest in expanding its portfolio within the healthcare technology sector.
Simulations Plus specializes in software and services that assist pharmaceutical and biotechnology companies in drug discovery and development. This acquisition aligns with recent trends where private equity firms have increased investments in health tech firms, seeking to capitalize on the growing demand for advanced simulation and modeling tools in drug development. Comparable deals in the sector have underscored the strategic value of such technology providers.
The transaction is anticipated to finalize by the end of the third quarter, with Altaris planning to leverage Simulations Plus’ existing capabilities to enhance its market position. The $375 million valuation underscores the company’s established role in the health tech industry and the confidence investors have in its growth potential.